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Abstract: There are no in vivo repeated-dose data for the vast majority of β-olefinic alcohols. 
However, there are robust and consistent ex vivo data suggesting many of these chemicals are 
metabolically transformed, especially in the liver, to reactive electrophilic toxicants which react 
in a mechanistically similar manner to acrolein, the reactive metabolite of 2-propen-1-ol. Hence, 
an evaluation was conducted to determine suitability of 2-propen-1-ol as a read-across analogue 
for other β-olefinic alcohols. The pivotal issue to applying read-across to the proposed category 
is the confirmation of the biotransformation to metabolites having the same mechanism of 
electrophilic reactivity, via the same metabolic pathway, with a rate of transformation sufficient 
to induce the same in vivo outcome. The applicability domain for this case study was limited to 
small (C3 to C6) primary and secondary -olefinic alcohols. Mechanistically, these -
unsaturated alcohols are considered to be readily metabolised by alcohol dehydrogenase to 
polarised α, -unsaturated aldehydes and ketones. These metabolites are able to react via the 
Michael addition reaction mechanism with thiol groups in proteins resulting in cellular apoptosis 
and/or necrosis. The addition of the non-animal in chemico reactivity data (50% depletion of free 
glutathione) reduced the uncertainty so the read-across prediction for the straight-chain olefinic 
-unsaturated alcohols is deemed equivalent to a standard test. Specifically, the rat oral 90-day 
repeated-dose No Observed Adverse Effect Level (NOAEL) for 2-propen-1-ol of 6 mg/kg body 
weight bw/d in males based on increase in relative weight of liver and 25 mg/kg bw/d in females 
based on bile duct hyperplasia and periportal hepatocyte hypertrophy in the liver, is read across 
to fill data gaps for the straight-chained analogues. 
Keywords: read across, No Observed Adverse Effect Level (NOAEL), β-olefinic alcohols, 
weight-of-evidence (WoE), uncertainty 
1 Introduction 
1.1 Read-across 
The basis for a toxicological read-across are chemicals which are similar in molecular structure, 
display similar chemical properties and in so doing have similar toxicokinetic and toxicodynamic 
properties. As a consequence, experimentally-derived toxicological properties from one 
compound, the source chemical, can be read across to fill the data gap for a second compound, 
the target chemical, which has been shown to be similar. This type of data gap filling may find 
particular use, for instance, for cosmetics ingredients where in vivo testing is prohibited by 
legislation in some geographic regions [1]. 
Read-across as a predictive tool has been used by industry and regulators for decades [2]. 
However, with the advances in non-animal test methods over the past 15 years, read-across 
arguments today are being held to a different standard than a decade ago, with greater 
expectation in terms of the certainties required from, and justification of, the read-across 
argument [3]. This is especially true for sub-chronic and chronic health effects.  
In order to facilitate the development of better guidance on how to formulate a high quality read-
across, a series of case studies have been conducted by the authors. This investigation describes a 
case study that has been designed to illustrate specific issues associated with an analogue 
approach [4] of the scenario where metabolism is the primary consideration in determining 
molecular similarity. The case study is intended to illustrate how non-animal data may be used to 
reduce uncertainties, as well as add to mechanistic plausibility and weight-of-evidence (WoE) to 
a read-across argument. 
One of the crucial issues in toxicological read-across is addressing substances that are altered 
metabolically to more toxic species [5]. The toxic metabolites of these indirect acting toxicants 
may be identical or different in structure within a group. In the former case, after in vivo dosing 
the various organs and systems of the animal are exposed to the same metabolite, thus 
toxicodynamic similarity may be assumed. In the latter case, after dosing the various organs and 
systems are exposed to metabolites with minor differences in chemical structure which may, or 
may not, elicit the same toxicological effects. This second situation adds complexity to the read-
across justification because of the burden of establishing both toxicokinetic and toxicodynamic 
similarity. 
The purpose of this investigation was to demonstrate the utility of non-animal methods to 
provide data and information that reduce uncertainties and add to the WoE associated with read-
across predictions of in vivo data. The proposed use of the estimations from this read-across is 
quantitative data gap filling with sufficiently low uncertainty that the predictions may be used in 
risk assessments. As such, the predicted NOAEL values are accompanied by sufficient non-
animal test data so the uncertainties are equal to do a test using a protocol similar to OECD TG 
408. In the present study, a previously reported ‘strategy’ [6] was employed to assess similarities 
and overall completeness of the read-across. The initial category included a wide variety of -
unsaturated alcohols. Based on consideration of a common metabolic pathway the tertiary 
alcohols and the -acetylenic alcohols (-alkynols) were eliminated from further consideration. 
Subsequently the olefinic -unsaturated alcohols were evaluated using relevant ex vivo, in 
chemico and in silico information. 
 
1.2 -Olefinic alcohols considered in this study and toxicological evidence 
Olefinic -unsaturated alcohols vary in molecular structure. These structural variations impact 
both reactivity and toxicity. While all olefinic alcohols contain a C=C moiety, they can be sub-
divided further according to whether the olefinic group is -, or non--oriented to the hydroxyl 
group. Additionally, they can be subdivided based on whether the hydrocarbon moiety is 
straight-chain or branched and whether the alcohol is primary, secondary or tertiary. These 
subdivisions are important for the toxicity effect as the overall structure of the parent alcohol 
determines the metabolic pathway and the specific metabolite formed. 
Only primary and secondary -olefinic alcohols can undergo first step oxidation to α, β-
unsaturated aldehydes or α, β-unsaturated ketones, respectively [7, 8]. While all of these 
oxidative metabolites have the capability to be reactive with biological macromolecules as 
Michael acceptors, they exhibit different levels of reactivity and toxicity [9-11]. 
Among the -olefinic alcohols, 2-propen-1-ol (i.e., 1-propen-3-ol; allyl alcohol) is the most 
studied derivative with a wide variety of toxicological data and information being reported. 
There is strong evidence that the mode of toxic action for 2-propen-1-ol involves metabolism via 
cytosolic alcohol dehydrogenase (ADH) to acrolein, an electrophile which elicits covalent 
cellular effects [12]. Overall, currently available data suggest that the kidney, liver and lung are 
potential targets for 2-propen-1-ol, following repeated oral or inhalation exposure. In oral 
repeated-dose toxicity testing, exposure to 2-propen-1-ol may lead to liver fibrosis [13, 14]. 
Liver fibrosis is a reversible response to acute or chronic hepatocyte injury [15-17]. The 
mechanistic rational is that the parent alcohol is relatively non-toxic; however its metabolite 
acrolein, a unique α, β-unsaturated aldehyde, is a Michael-type soft electrophile. Such 
electrophiles preferentially interact covalently with thiol groups in proteins leading to necrotic or 
apoptotic cell death [18]. During the in vivo response to cell death, stellate cells in the liver are 
activated, for example by transforming growth factor beta (TGF-β) and connective tissue is 
formed [19]. 
Historically, the hepatotoxic action of 2-propen-1-ol to rodent liver is related to oxidative 
metabolism to acrolein which, in turn, can bind covalently to proteins in periportal hepatocytes 
[20, 21]. The covalent binding of acrolein to hepatic proteins was also confirmed by a study on 
radiolabelled 14C 2-propen-1-ol and its deuterated derivative [22]. Two-propen-1-ol exerts a 
dose-dependent toxicity on cells, which is inversely related to the concentration of cellular GSH 
[23]. After severe depletion of GSH, the reactive metabolite of 2-propen-1-ol – acrolein - can 
bind to essential sulfhydryl groups in the cellular macromolecules, leading to cellular damage 
[13]. The toxicity of 2-propen-1-ol can be prevented by inhibitors of ADH and augmented by the 
aldehyde dehydrogenase (ALDH) inhibitor disulfiram [23]. 
In vivo oral exposure to 2-propen-1-ol leads to periportal necrosis and subsequent connective 
tissue development [12, 14]. Histopathological studies of 2-propen-1-ol exposed to repeatedly 
dosed rat livers showed signs of necrosis around the portal triad, with relatively little damage 
around the central vein. In addition, ductular proliferation, connective tissue accumulation and 
cirrhosis were evident. 
 
2 Method and Materials 
This evaluation of selected -olefinic alcohols followed a read-across workflow proposed by 
Schultz et al (2015) [6]. It is in accord with the guidance proposed by Organization for Economic 
Co-Operation and Development (OECD) (2015) [24]. In vivo data used in the assessment were 
taken from the literature, including ECHA REACH Registered Substances database [25]. 
Mechanistic relevance, as well as, toxicokinetic and toxicodynamic similarity of the category 
analogues was established using relevant non-animal data. 
 
2.1 Target and Source Substances 
The analogues that were evaluated are listed in Table 1 and include 15 potential target substances 
and one source chemical (noted in bold). This list is not meant to be all inclusive, rather it 
represents existing industrial organic materials that are likely to be found in a governmental or 
industrial inventory (e.g., OECD High Production Volume Chemicals). Additional substance 
identifier information, such as chemical structures and molecular formulas are available in the 
Table 1 of the supplemental information. Based on extended structural fragments, the β-olefinic 
alcohol category includes five sub-groups (Figure 1). These sub-groups can be clustered into two 
sub-categories – straight-chained and branched β-olefinic alcohols. 
Table 1. Potential category analogues for β-olefinic alcohols. 
ID Name CAS No SMILES Type of Alcohol 
Straight-chained 
1 2-Propen-1-ol ( allyl 
alcohol) 
107-18-6 OCC=C prim. 
allylic 
terminal OH & C=C 
2 2-Buten-1-ol 6117-91-5 OCC=CC prim. allylic terminal OH, internal C=C 
3 2-Penten-1-ol 20273-24 OCC=CCC prim. allylic terminal OH, internal C=C 
4 2-Hexen-1-ol 2305-21-7  OCC=CCCC prim. allylic terminal OH, internal C=C 
5 1-Buten-3-ol 598-32-3 C=CC(O)C sec. allylic internal OH, terminal C=C 
6 1-Penten-3-ol 616-25-1 C=CC(O)CC sec. allylic internal OH, terminal C=C 
7 1-Hexen-3-ol 4798-44-1 C=CC(O)CCC sec. allylic internal OH, terminal C=C 
8 3-Penten-2-ol 1569-50-2 CC(O)C=CC sec. allylic internal OH & C=C 
9 3-Hexen-2-ol 42185-97-7 CC(O)C=CCC sec. allylic internal OH & C=C 
10 4-Hexen-3-ol 4798-58-7 CCC(O)C=CC sec. allylic internal OH & C=C 
Branched-chained 
11 2-Methyl-2-propen-1-ol 513-42-8 OCC(C)=C prim. allylic terminal OH & C(C)=C 
12 2-Methyl-2-buten-1-ol 4675-87-0 OCC(C)=CC prim. allylic terminal OH, internal 
C(C)=C 
13 2-Methyl-2-penten-1-ol 1610-29-3 OCC(C)=CCC prim. allylic terminal OH, internal 
C(C)=C 
14 3-Methyl-2-buten-1-ol 556-82-1 OCC=C(C)C prim. allylic terminal OH, internal 
C=C(C) 
15 3-Methyl-3-penten-2-ol 2747-53-7 CC(O)C(C)=CC sec. allylic internal OH & C(C)=C 
16 4-Methyl-3-penten-2-ol 4325-82-0 CC(O)C=C(C)C sec. allylic internal OH & C=C(C) 
CAS No - chemical abstracts service number 
SMILES - simplified molecular-input line-entry system 
 
 
 
Figure 1. Five sub-categories of β-olefinic alcohols. 
 
2.2 Endpoint 
The NOAEL for the 90-day rat oral repeated-dose is the single endpoint for which this analogue 
approach to read-across is applied. The 90-day oral repeated-dose data for 2-propen-1-ol (allyl 
alcohol) are well suited for reading across; the multiple reported NOAELs are highly similar 
both qualitatively and quantitatively, based on experimental results from 4-or 5-dose exposure 
scenarios, and follow test guidelines similar to OECD TG 408. 
2.3 Hypothesis of the category 
The premise for this read-across case study is: 
 Primary and secondary β-olefinic alcohols of short chain length (i.e., C3 to C6) are 
indirect-acting toxicants (i.e., metabolism is critical factor in toxicity) with the same 
covalent mechanism of action (i.e., Michael addition electrophilicity) and similar reactive 
potency. 
 Within the C3 to C6 derivatives, C-atom chain length or branching does not significantly 
affect oral bioavailability. 
 Whilst all short-chain β-olefinic alcohols are rapidly and nearly completely absorbed 
from the gut; only the primary and secondary alcohols are capable of being metabolised, 
primarily in the liver, via ADH. 
 Oxidative metabolism of primary and secondary β-olefinic alcohols results in the 
corresponding α, β-unsaturated aldehyde or α, β-unsaturated ketone. 
 These α, β-unsaturated aldehydes or α, β-unsaturated ketones are the definitive 
electrophilic toxicants and their in vivo potency is related to relative thiol reactivity; thus, 
only β-unsaturated alcohols with metabolism similar to 2-propen-1-ol and reactive 
potency similar to acrolein may be read across for 2-propen-1-ol with reasonable 
certainty. 
3 Results 
3.1 Read across justification 
In order to conduct a read-across there is the requirement for high quality in vivo data for the 
endpoint under consideration [6, 24] which, in this case, is 90-day oral repeated dose-toxicity for 
rat in the form of a NOAEL value. 
 
3.1.1 Rodent repeated-dose toxicity for 2-propen-1-ol 
In general, toxicological data on 2-propen-1-ol demonstrate significant toxicity. The oral LD50 
for rat is 37 mg/kg for 2-propen-1-ol [26], while the rat oral LD50 for the saturated isomer 1-
propanol is 1870 mg/kg [27]. 
Several 90-day oral repeated-dose toxicity evaluations of 2-propen-1-ol have been conducted 
according to test guidelines similar to OECD TG 408. Male and female Long-Evans rats were 
exposed orally to 0, 0.17, 0.94, 7.3, 13.2, 34.0, 43.7, and 67.4 mg/kg bw/d (females) and 0, 0.13, 
0.62, 5.9, 11.6, 25.5, 41.0, and 72.0 mg/kg bw/day (male) for 13 weeks [29]. The No Observed 
Adverse Effect Level (NOAEL) of 13.2 mg/kg bw/d (for females) and 11.6 mg/kg bw/d for male 
were reported. This observation was based on increases in relative kidney (both sexes) and liver 
weights (males) [28]. 
In another study, male and female Wistar rats were exposed orally to 0, 4.8, 8.3, 14.0 and 48.2 
mg/kg bw/d (males) and 0, 6.2, 6.9, 17.1 and 58.4 mg/kg bw/d (females) for 15 weeks [29]. The 
reported NOAEL, based on increases in relative kidney weight and decrease in water intake and 
body weight, was 4.8 and 6.2, mg/kg bw/d for male and female respectively. 
In a third study, mixed sexes of F344/N rats and B6C3F1 mice were exposed to 2-propen-1-ol by 
gavage to 0, 1.5, 3, 6, 12, or 25 and 0, 3, 6, 12, 25, or 50 mg/kg bw/d, respectively for 14 weeks 
and the clinical chemistries were examined in detail [30]. The major toxic response in both mice 
and rats occurred in the forestomach and the NOAEL values derived from this toxic effect were 
3 and 6 mg/kg bw/d for mice and rats, respectively. However, the treatment with the highest 
evaluated dose, 25 mg/kg, significantly increased the incidences of bile duct hyperplasia and 
periportal hepatocellular hypertrophy in female rats but not in males. For male rats, the increase 
in relative weight of liver was observed at a dose of 6 mg/kg. The sex difference in 2-propen-1-ol 
hepatotoxicity in rats was also reported by Rikans and Moore [31] and was explained by the 
greater alcohol dehydrogenase activity in female rats than in male rats. Also in mice, females 
were more responsive than males, and increased incidences of portal cytoplasmic vacuolisation 
occurred in 12 mg/kg or greater in females; whereas in males, this lesion was first observed at 25 
mg/kg [30]. However, these differences in hepatotoxic responses between male and female rats 
seem not to be relevant to this case study as they should be observed for other β-olefinic 
alcohols. Based on the effects in the liver, the NOAEL values of 6 and 25 mg/kg bw/day in male 
and female rats, respectively, have been established. 
 
3.1.2 Rodent repeated-dose toxicity for other β-olefinic alcohols 
The second β-olefinic alcohol tested in acute toxicity tests as well as the 90 days repeat dose 
assay is 3-methyl-2-buten-1-ol. The LD50 for the rat after oral administration of 3-methyl-2-
buten-1-ol is 810 mg/kg with symptoms such as: apathy, dyspnoea, redness of eyes and ears [32]. 
To our knowledge, the findings of only one 90-day oral repeated-dose toxicity evaluation of 3-
methyl-2-buten-1-ol are publicly available [33-35]. Following OECD Test Guideline 408, 3-
methyl-2-buten-1-ol was administered to groups of 10 male and 10 female Wistar rats via 
drinking water at concentrations of 14.4, 65.4 and 243.8 mg/kg bw/day for male and 21.0, 82.1 
and 307.2 mg/kg bw/day for female for three months [33]. Substance related effects were seen at 
the high and mid dose levels. In the mid dose groups, decreased food and water consumption in 
male rats and reduced water consumption in female rats were noted. Body weight was 
significantly impaired at the high dose in male and female rats. In the mid and high dose, the 
mean absolute liver weights in male rats were significantly decreased, but not the relative liver 
weights. There were no other treatment related significant changes in clinical examinations. As 
reduction in food and water consumption resulted in significant decrease of body weight only at 
the high dose level, the NOAEL was assessed to be 65.4 mg/kg bw/day in male rats and 82.1 
mg/kg bw/day in female rats. 
It is noted that two more sub-acute oral studies in rats do not show any other effects of 3-methyl-
2-buten-1-ol. Specifically, a 14-days drinking water study with rats (3/sex/dose) exposed to 250, 
500, 750 and 1500 mg/kg bw/d reported acute toxic effects at 1500 mg/kg bw/d; reduced food 
and water intake was observed at 250 mg/kg bw/d [32]. So there is good concordance with 90-
day test results. In a 14-day gavage test with rats exposed to 250, 500 and 750 mg/kg bw/d no 
treatment related effects were observed [36]. 
In summary, while protocols vary, three studies have experimentally evaluated 2-propen-1-ol 
and one study evaluated 3-methyl-2-buten-1-ol in 90-day, oral repeated-dose testing schemes. 
Repeated-dose toxicity data on 2-propen-1-ol indicate liver and kidney are the target organs. For 
the 3-methyl-2-buten-1-ol, only the reduction in food and water consumption was observed. The 
90-day NOAEL values for oral administration are between 3 and 15 mg/kg bw/d for 2-propen-1-
ol and 60 -85 mg/kg bw/d for 3-methyl-2-buten-1-ol (see Table 8 of the supplemental 
information). These ranges of NOAEL values are 10-100 times smaller than those reported for 
saturated derivatives (data not shown). 
 
3.1.3 Applicability domain 
After elimination of tertiary alcohols and -alkynols, the applicability domain was limited to 
subclasses of -olefinic aliphatic alcohols with carbon chain lengths from C3 to C6. Specifically, 
these included primary (external hydroxyl group) and secondary (internal hydroxyl group) with a 
-positioned vinylic moiety (Table 1). 
 
3.1.4 Purity/impurities 
A purity/impurity profile for the analogue listed in Table 1 is not reported. No effort was made to 
take into account impurities based on production. However, since the category is structurally 
limited, the potential impact of any impurities on the endpoint being evaluated is considered very 
limited. The most likely impurities are saturated derivatives or isomers (e.g. cis vs. trans 
conformations or S/R stereoisomers). 
 
3.2 Data matrices for assessing similarity 
In order for a read-across prediction to be accepted there is the requirement to establish similarity 
between the source and target substance [6, 24]. While structural similarity is a minimum, 
toxicokinetic similarity, especially for metabolism, and toxicodynamic similarity, especially in 
regard to mechanistic plausibility is required for chronic endpoints such as 90-day oral repeated 
dose-toxicity [6, 24]. 
 
3.2.1 Structural similarity 
As demonstrated in Table 1 and Table 3 of the supplemental information, all the β-olefinic 
alcohols included in the category are structurally similar (e.g., C3-C6). Specifically, they: 1) 
belong to a common chemical class, β-unsaturated alcohols, 2) the subclass β-olefinic alcohols, 
and 3) possess one of two molecular scaffoldings, primary with an external hydroxyl or 
secondary with an internal hydroxyl configuration. Structural similarity is complicated by the 
presence or absence of alkyl substituents (i.e., methyl groups) on the allylic moiety. The potential 
source substance, 2-propen-1-ol, is a unique β-olefinic alcohol, one with both a terminal 
hydroxyl and terminal vinyl group. In contrast, two other potential category members, 3-methyl-
2-buten1-ol and 4-methyl-3-penten-2-ol, are dissimilar as they have an alkyl substituent on the 
olefinic carbon that can inhibit the protein binding site of the vinyl group. 
 
3.2.2 Chemical property similarity 
As demonstrated in Table 2 of the supplemental information, all the β-olefinic alcohols included 
in the category have a very narrow value range for their physico-chemical properties. 
Specifically, all category members exhibit molecular weights from 58 to 100 g/mol. While 
hydrophobicity (log Kow) increases with number of C-atoms from 0.17 to 1.66, density is 
constant at 0.8 +/- 0.1 g/cm3. Vapour pressure and water solubility decrease with molecular size 
and therefore vary only slightly within the category. All category members are liquids over the 
typical temperature range as melting points are all well below 0 °C and boiling points are all 
around or above 100 °C. 
 
3.2.3 Chemical constituent similarity 
As demonstrated in Table 3 of the supplemental information, all the β-olefinic alcohols include 
in the category have common constituents in the form of: 1) a single polar substituent, -OH, 2) a 
β-positioned olefin (C=C) moiety. Other structural fragments are limited to -H, -CH3 and -CH2- 
groups. 
 3.2.4 Toxicokinetic similarity  
As shown in Table 4 of the supplemental information, the toxicokinetic understanding of primary 
and secondary β-olefinic alcohols is incomplete. The oxidation of primary alkanols and primary 
olefinic alcohols to the corresponding aldehydes is catalysed by NAD+/NADH-dependent ADH 
[37]. Olefinic alcohols were better substrates for human liver ADH than the corresponding 
saturated alcohols. A comparison of the alcohol structure with the enzyme binding affinity of 
alcohol dehydrogenase indicates that increased binding (lower Km) occurs with increasing chain 
length (C3-C6) of the alcohols and the presence of unsaturation. Specifically, binding affinities 
with human liver ADH were measured in vitro for 2-propen-1-ol, 2-buten-1-ol, 3-methyl-2-
buten-1-ol and 2-hexen-1-ol and they are: 0.05, 0.01, 0.0045 and 0.003 mM, respectively [37]. 
With the exception of 2-propen-1-ol, the Km values of unsaturated alcohols are 14-20 times 
lower than for the corresponding saturated alcohols (Km = 0.10, 0.14, 0.07 and 0.06 for 1-
propanol, 1-butanol, 3-methyl- 1-butanol and 1-hexanol, respectively) [37]. The maximum rates 
of oxidation were essentially constant, regardless of the alcohol structure, suggesting that 
alcohol-enzyme binding is not the rate-limiting step for oxidation [38]. The activity of the 
enzyme appears to be dependent on the lipophilic character of the alcohol. Another study on 
biotransformation of 2-propen-1-ol by rat lung and liver preparations showed that 80 % of 
alcohol was metabolised to acrolein when liver supernatant and cytosol fractions were used [39]. 
2-propen-1-ol did not appear to be metabolised to acrolein when lung fractions were used.  
Fontaine et al. [40] studied the enzymatic formation of 2-butenal from the β-olefinic alcohol, 2-
buten-1-ol. This is analogous to the manner in which allyl alcohol is converted in vivo to its toxic 
oxidative product, acrolein. In kinetic studies it was found that 2-buten-1-ol was readily oxidised 
by equine liver ADH, with electrospray-mass spectrometry confirming that 2-butanal was the 
main metabolite formed. It was also reported that in mouse hepatocytes, 2-buten-1-ol produced 
marked time- and concentration-dependent cell killing as well as pronounced glutathione 
depletion. Most importantly, both cytotoxicity and glutathione loss were eliminated with the 
addition of the ADH inhibitor 4-methylpyrazole, indicating the ADH-mediated pathway is 
responsible for producing these effects. In keeping with expectations that Michael addition 
adducts would feature prominently during protein modification, Fontaine and co-workers [40] 
note that exposure to 2-buten-1-ol resulted in marked carbonylation of a range of cell proteins. 
Damage to a subset of small proteins (e.g., 29, 32, 33 kDa) is closely correlated with the severity 
of cell death. This cytotoxicity, as well as glutathione depletion, were eliminated by the addition 
of 4-methylpyrazole. Collectively, these results demonstrate that for the model β-olefinic 
alcohol, 2-buten-1-ol, toxicity via Michael addition is accompanied by ADH-mediated 
metabolism. 
Further oxidation of the aldehyde produces the corresponding acid. However, Patel et al. [39] 
showed that only 15% of the acrolein was metabolised to acrylic acid. The corresponding 
carboxylic acid may enter the -oxidation pathway and be subsequently metabolised to CO2 via 
the tricarboxylic acid pathway or be glucuronidated prior to excretion in the urine. However, this 
detoxification is not considered to be relevant to repeated-dose toxicity. 
Secondary alcohols are expected to be excreted via conjugation or oxidised to ketones, which 
cannot be further oxidised. Additionally, they can be excreted unchanged or undergo 
hydroxylation of the carbon chain, which in turn may give rise to a metabolite that can be more 
readily excreted. 
 
3.2.5 Metabolic similarity 
As demonstrated in Table 5 of the supplemental information, all of the β-olefinic alcohols 
included in the category are predicted by in silico tools to be metabolised via oxidation to the 
corresponding α, β-unsaturated aldehydes or α, β-unsaturated ketones. Other biotransformation 
pathways, such as hydroxylation and epoxidation are also predicted. These soft electrophiles 
subsequently react with GSH and protein thiols in hepatocytes [40, 41]. 
From a structural standpoint, only primary and secondary β-olefinic alcohols are able to be 
activated by ADH to form polarised α, β-unsaturated electrophiles [7]. The availability of H-
atoms on the C-atom with the hydroxyl OH group is crucial to the metabolic activation and 
subsequent expression of relative toxic potency. Primary alcohols have one alkyl-group; thus, 
two H-atoms are available for metabolism. Secondary alcohols have two alkyl-groups and one 
H-atom available for alcohol dehydrogenase attack. Tertiary alcohols are substituted with three 
alkyl-groups on the α-carbon; thus, no H-atoms are available for metabolism. Since at least one 
H-atom must be freely available for cleavage by ADH, tertiary alcohols are not metabolised to 
Michael acceptor electrophilic derivatives by ADH [42]. It follows that primary β-olefinic 
alcohols are likely to be more readily converted to reactive metabolites than secondary ones. 
The finding of Moridani et al. [43] suggests that the primary β- acetylenic alcohol, 2-propyn-1-
ol, induces cytotoxicity via metabolic activation by CYP 2E1 to form 2-propynal which in turn 
causes hepatocyte lysis as a result of GSH depletion and lipid peroxidation. Specifically, 2-
propyn-1-ol-induced cytotoxicity was marked by enhanced CYP 2E1-induced hepatocytes and 
prevented by various CYP 2E1 inhibitors. Moreover, the authors further reported that 
cytotoxicity of 2-propyn-1-ol was only slightly affected when ADH was inhibited with 4-
methylpyrazole or when liver catalase was inactivated with azide or aminotriazole. However, 
cytotoxicity was prevented when lipid peroxidation was inhibited with antioxidants, 
desferoxamine or dithiothreitol. Additionally, the authors found out that hepatocyte GSH 
depletion preceded cytotoxicity and can be inhibited by cytochrome P450 inhibitors but not by 
liver catalase and ADH inhibitors. Two-propyn-1-ol –induced cytotoxicity and reactive oxygen 
species formation were markedly increased in GSH-depleted hepatocytes [43]. Therefore, based 
on metabolic similarity, the read-across category is limited to primary and secondary β-olefinic 
alcohols which differ from β- acetylenic alcohols in the activation pathway. 
 
3.2.6 Toxicophore similarity 
As demonstrated in Tables 6A and 6B of the supplemental information, based on in silico 
predictions, only the metabolites of β-olefinic alcohols and not the parent compounds triggered 
the OECD DNA and protein binding profilers within the OECD QSAR Toolbox v3.3.5. With the 
exception of 3-methyl-2-butenal and 4-methyl-3-penten-2-one, all relevant metabolites of β-
olefinic alcohols are associated with Michael addition mechanisms. The potency of protein 
binding varies consistently between the five sub-structural groups that can be accounted for by 
sub-categorisation of β-olefinic alcohols. 
 
3.2.7 Mechanistic plausibility similarity 
Reactivity with biological molecules consists of a variety of conjugation, substitution, and 
addition reactions, which have their foundation in the principles of organic reactions [8]. As 
summarised in Table 7 of the supplemental information, the β-olefinic alcohols included in the 
category are associated via covalent interaction with thiols. This mechanism is based on ADH-
induced Michael addition [8]. 
As noted by Richarz et al. [44], the over-arching toxic pathway involves metabolic activation to 
soft electrophilic derivatives which prefer to covalently interact with thiol-containing cellular 
nucleophiles (e.g., glutathione). Cellular events include dose-dependent necrosis or 
mitochondrial-based apoptosis; whereas liver and kidney are the target organs. 
Landesmann et al. [45] reported a preliminary adverse outcome pathway (AOP) leading from the 
molecular initiating event of covalent protein binding to the adverse effect of liver fibrosis. They 
noted a number of key intermediate events including: 
 Hepatocyte injury and death 
 Activation of Kupffer cells (liver macrophages) 
 Inflammation 
 Oxidative stress 
 Activation of TGF- β 
 Activation of stellate cells (mesenchymal stem cells) 
 Collagen synthesis and accumulation 
 Alteration in connective tissue extracellular matrix 
This AOP was constructed, in large part, from data on 2-propen-1-ol and its metabolite - 
acrolein. The molecular initiating event of this pathway is covalent binding to thiols. More 
specifically, upon reaching the liver, the non-reactive parent alcohol is converted enzymatically 
to the corresponding α, β-unsaturated aldehyde or α, β-unsaturated ketone. These reactive 
species, in turn, bind to thiols such as GSH. Once GSH is dissipated, the α, β-unsaturated 
substrates react with other cellular thiols, especially in mitochondrial proteins. This denaturing of 
proteins leads to apoptosis or necrosis of hepatocytes and subsequent events along the AOP. 
The short-term isolated perfused liver represents an ex vivo model which is close to the in vivo 
condition. The major advantages are that the three-dimensional architecture of the liver and the 
metabolic capabilities of the hepatocytes are preserved. Strubelt et al. [18] studied acute toxicity 
and metabolism in a series of short-chain alcohols. Specifically, the effects of 23 alcohols at a 
single concentration (65.1 mmol/L) in isolated rat livers perfused at 60 ml/hr for two hours were 
examined. The authors demonstrated that, for straight-chain saturated primary alcohols, hepatic 
cell injury measured by the release of three cytosolic enzymes into the perfusate and reduction in 
oxygen consumption were directly related to chain length. In most cases, hepatic ATP 
concentrations decreased in a similar manner to hepatic cell injury and oxygen consumption [18] 
Ex vivo toxicity profiles for selected -unsaturated alcohols are reported in Table 2. 
Table 2. Ex vivo toxicity profiles for β-olefinic alcohols. 
ID Name 
LDH 
(U/l) 
O2 consumption 
(µmol/g x min) 
ATP 
(mol/g) 
GSH 
(mol/g) 
 Control 1109 ± 265 1.54 ± 0.07 1.25 ± 0.20 2.52 ± 0.29 
Straight-chained 
1 2-Propen-1-ol  27747 ± 2756 0.10 ± 0.01 0.07 ± 0.01 0.28 ± 0.12 
2 2-Buten-1-ol 10977 ± 2433 0.47 ± 0.06 0.11 ± 0.01 0.02 ± 0.01 
3 2-Penten-1-ol     
4 2-Hexen-1-ol     
5 1-Buten-3-ol 25756 ± 1355 0.19 ± 0.04 0.09 ± 0.00 0.03 ± 0.00 
6 1-Penten-3-ol     
7 1-Hexen-3-ol     
8 3-Penten-2-ol     
9 3-Hexen-2-ol     
10 4-Hexen-3-ol     
Branched-chained 
11 2-Methyl-2-propen-1-ol 15552 ± 3282 0.45 ± 0.01 0.15 ± 0.01 0.04 ± 0.02 
12 2-Methyl-2-buten-1-ol     
13 2-Methyl-2-penten-1-ol     
14 3-Methyl-2-buten-1-ol 7738 ± 1460 0.84 ± 0.24 0.55 ± 0.22 0.26 ± 0.07 
15 3-Methyl-3-penten-2-ol     
16 4-Methyl-3-penten-2-ol     
β-acetylenic 
17 2-Propyn-1-ol 13743 ± 2457 0.19 ± 0.05 0.14 ± 0.02 0.08 ± 0.05 
Saturated 
18 1-Propanol  4731 ± 1867 1.66 ± 0.13 0.98 ± 0.19 
19 1-Butanol  8946 ± 2411 0.98 ± 0.40 0.88 ± 0.09 
20 1-Pentanol  28959 ± 4142 0.06 ± 0.01 0.22 ± 0.03 
21 2-Methyl-1-propanol  11499 ± 2898 0.88 ± 0.10 0.53 ± 0.05 
22 3-Methyl-1-butanol  8680 ± 1216 0.22 ± 0.07 0.10 ± 0.01 
23 2-Methyl-2-butanol  9353 ± 2582 1.13 ± 0.33 0.62 ± 0.23 
24 2-Methyl-3-butyn-2-ol  2078 ± 1524 1.20 ± 0.20 0.68 ± 0.07 
LDH – lactate dehydrogenase; ATP - adenosine triphosphate; GSH – reduced glutathione 
 
Testing using isolated perfused liver demonstrated that saturated alcohols elicited no change in 
GSH levels. In contrast, unsaturated straight-chain alcohols, including allyl alcohol caused 
significant reductions in GSH [18]. 
The major weakness of the Strubelt study is the lack of dose-response data. However, the results 
of the Strubelt study support the premise that 1-alken-3-ols, 2-alken-1-ols, and 2-methyl-2-alken-
1-ols are metabolised and give rise to a metabolite of similar potency to 2-propen-1-ol and thus 
are very likely to cause similar repeated-dose toxicity. The data in Table 2 also support the 
structural selectivity of the category as tertiary β-unsaturated alcohols, as well as alkanols, do not 
reduce GSH (i.e., are not metabolised to reactive electrophiles). Moreover, they do not elicit the 
same repeated-dose effects. The structural saturated analogue of 2-propen-1-ol – 1-propanol was 
tested in rats for four months at the dose of 3000mg/kg bw/d [46]. Food consumption, body 
weight gain, and liver histopathology were comparable to those of the control group. 
Additionally, the 90 day oral repeat-dose toxicity NOEL for 2-propanol in rat was reported as 
870 mg/kg bw/d, based on the relative organ weights of liver, kidneys, and adrenals [47]. 
 3.2.8 Other endpoint similarity 
The basic structure-activity relationships for chemical reactivity via Michael addition to thiols 
are pivotal for understanding both in vitro and in vivo hepatotoxic potency. 
Acrolein is unique amongst the , -unsaturated carbonyl compounds as it is the only molecular 
structure having both a terminal vinyl group and a terminal carbonyl group. These structural 
features associated with relative reactivity of polarised , -unsaturated molecules, especially 
where an olefinic moiety conjugated to a carbonyl group, towards the model nucleophile 
glutathione, have been examined [10]. This , -unsaturated structure conveys the capacity to 
undergo a covalent interaction with the thiol group of cysteine in the form of Michael addition 
[8]. Quantitatively, reactivity of the , -unsaturated carbonyl compounds with glutathione is 
reliant upon the specific molecular structure, with several trends being observed and reported [8, 
10]. In chemico reactivity data (RC50 values) in the form of the depletion of GSH after 120-
minutes by selected , -unsaturated carbonyl compounds are reported in Table 3. 
Table 3. In chemico reactivity profiles for α, β-unsaturated aldehydes and ketones. 
ID Alcohol Metabolite Metabolite SMILES GSH RC50 
Straight-chained 
1 2-Propen-1-ol 2-Propenal (acrolein) O=CC=C 0.085 
2 2-Buten-1-ol 2-Butenal (crotonaldehyde) O=CC=CC 0.22 
3 2-Penten-1-ol trans-2-Pentenal O=CC=CCC 0.35 
4 2-Hexen-1-ol trans-2-Hexenal O=CC=CCC 0.42 
5 1-Buten-3-ol Methyl vinyl ketone C=CC(=O)C 0.070 
6 1-Penten-3-ol Ethyl vinyl ketone C=CC(=O)CC 0.051 
7 1-Hexen-3-ol Propyl vinyl ketone C=CC(=O)CCC 0.059 
8 3-Penten-2-ol 3-Penten-2-one CC(=O)C=CC 0.15 
9 3-Hexen-2-ol 3-Hexen-2-one CC(=O)C=CC not tested 
10 4-Hexen-3-ol 4-Hexen-4-one CCC(=O)C=CC 0.34 
Branched-chained 
11 2-Methyl-2-propen-1-ol 2-Methyl acrolein O=CC(C)=C not tested 
12 2-Methyl-2-buten-1-ol 2-Methyl-2-butenal O=CC(C)=CC 12 
13 2-Methyl-2-penten-1-ol 2-Methyl-2-pentenal O=CC(C)=CCC 21 
14 3-Methyl-2-buten-1-ol 3-Methyl-2-butenal O=CC=C(C)C 13 
15 3-Methyl-3-penten-2-ol 3-Methyl-3-penten-2-one CC(=O)C(C)=CC 10 
16 4-Methyl-3-penten-2-ol 4-Methyl-3-penten-2-one CC(=O)C=C(C)C 26 
Saturated 
17 1-Propanol 1-Propanal/1-Propionic acid CCC=O/CCC(=O)O not reactive at 1000 mg/l 
18 1-Butanol 1-Butanal/1-Butyric acid CCCC=O/CCCC(=O)O not reactive at 1000 mg/l 
19 1-Pentanol 1-Pentanal/1-Pentanoic acid CCCCC=O/CCCCC(=O)
O 
not reactive at 1000 mg/l 
20 2-Methyl-1-propanol 2-Methyl-1-propanal/2-
Methyl-1-propionic acid 
CC(C)C=O/CC(C)C(=O)
O 
not reactive at 1000 mg/l 
21 3-Methyl-1-butanol 3-Methyl-1-butanal/2-
Methyl-1-butyric acid 
CC(C)CC=O/CC(C)CC(
=O)O 
not reactive at 1000 mg/l 
22 2-Methyl-2-butanol 2-Methyl-2-butanone CC(C)C(=O)C not reactive at 1000 mg/l 
23 2-Methyl-3-butyn-2-ol not metabolised - not reactive at 500 mg/l 
 
Specifically, it has been reported that for , -unsaturated carbonyl compounds, such as those 
derived from hepatic oxidative metabolism of -olefinic alcohol, the: 1) terminal vinyl-
substituted derivatives (H2C=C-) were more reactive than the internal vinylene-substituted ones 
(-CH=CH-); 2) methyl-substitution on the vinyl carbon atoms diminishes reactivity, 3) methyl-
substitution on the carbon atom farthest from the carbonyl group (C(=O)C=C(C) causes a larger 
reduction than methyl-substitution on the carbon atom nearest to the carbonyl group 
(C(=O)C(C)=C), and 4) derivatives with a carbon-carbon double bond at the end of the molecule 
(i.e., vinyl ketones) were more reactive than ones with the carbon-oxygen double bond at the end 
of the molecule (i.e., aldehydes). 
The results from the measurement of thiol reactivity (see Table 3) suggest that the ability of , -
unsaturated carbonyl compounds other than acrolein (and thus, -olefinic alcohol other than 2-
propen-1-ol) to elicit kidney and liver targeted toxicity may be reduced, especially for branched 
alcohols with alkyl substitutions on the vinyl carbon atoms. 
In fish, the mode of (acute) toxic action involves metabolism of the parent alcohol to the 
corresponding α, β-unsaturated aldehyde or ketone via alcohol dehydrogenase [42, 48]. The 
conventional thinking is that, whilst the parent aliphatic alcohols elicit baseline toxic action 
through narcosis, the metabolites are electrophilic toxicants. Specifically, the metabolites are 
polarised α, β-unsaturated chemicals which undergo a Michael-type addition to soft nucleophilic 
sites in proteins [8]. Bradbury and Christensen [7] confirmed the role of alcohol dehydrogenase 
activity in metabolic activation and enhanced toxicity in fish. Specifically, the alcohol 
dehydrogenase in the gill epithelial cells metabolises the appropriate alcohol to the 
corresponding aldehyde (or ketone), which in turn reacts with cellular proteins. The end result is 
death of the gill epithelia cells, which results in the loss of the ability to extract oxygen causing 
subsequent hypoxia and fish mortality. This mechanism was described for model electrophiles 
by respiratory and cardiovascular responses in trout [49]. 
Acute toxicity studies with the fathead minnow (Pimephales promelas) found that primary and 
secondary allylic alcohols and primary and secondary propargylic alcohols exhibit potency in 
excess of that predicted by saturated alcohols and baseline narcosis QSAR models [48, 50]. 
However, tertiary olefinic and tertiary acetylenic alcohols exhibit fish toxic potency consistent 
with baseline narcosis models. The enhanced toxicity of acetylenic alcohols is thought to be due 
to metabolic activation to electrophilic α, β-unsaturated propargylic aldehydes or ketones. For 
primary and secondary homopropargylic alcohols, an activation step involving biotransformation 
to an allenic electrophile intermediate was proposed [42]. The results from fish acute toxicity 
experiments support the premise that the basic structure-activity relationships for chemical 
reactivity via Michael additions to thiol is key for understanding mammalian repeated-dose toxic 
potency of β-unsaturated alcohols. 
 
3.3 Uncertainty in similarities 
Data uncertainty and weight-of-evidence associated with the fundamentals of chemistry, as well 
as toxicokinetic and toxicodynamic similarity of category members is presented in Table 4. 
 
3.3.1 Uncertainty in chemical similarities 
The similarities in physico-chemical properties are reduced by the narrow structural range (i.e., 
C3 to C6) of the category. Moreover, the differences in chemical property values are not 
considered to be toxicologically relevant. In terms of structure, the complex extended fragment 
of the applicability domain of this category results in moderate similarity across the analogues in 
Table 1. The key feature, being a primary or secondary -olefinic alcohol of short-chain length is 
common within the category and is relevant to the toxicity read across. The extended fragment 
differences among the category members are best presented with their 2D structure. These 
differences are related to the location of hydroxyl group: external (primary alcohols) and internal 
(secondary alcohols); the position of the unsaturated moiety, which can be either internal or 
external and the substitution of vinyl group carbon atoms with alkyl group (e.g., methyl group). 
Amongst the category members, the source substance, 2-propen-1-ol, is a structurally unique β-
olefinic alcohol with both a terminal vinyl group and a terminal hydroxyl. Additionally, the 
presence of geometric isomerism or stereoisomerism among the different category members 
reduces the chemical similarity and can affect the reproducibility of test results as well as 
metabolism and reactivity.  
Structural differences within the β-olefinic alcohols lead to 1) different likely metabolite (e.g., 
aldehyde or ketone), 2) different ex vitro metabolism (i.e., free GSH levels) and 3) different rates 
of in chemico reactivity (i.e., GSH reactivity). However, it is uncertain if these short-term (i.e., 2-
hour) differences are relevant to repeated-dose toxicity. 
Table 4. Data uncertainty and weight-of-evidence associated with the fundamentals of 
chemistry, transformation/toxicokinetic and toxicodynamic similarities 
Similarity 
Parameter 
Data 
Uncertainty a 
Strength of 
Evidence b 
Comment 
Substance 
Identification, 
Structure and 
Chemical 
Classifications 
Low High All category members are discrete organic substance of 
simple structure. They all have CAS numbers, similar 
2D structure and belong to the same chemical class and 
one of five noted subclasses. The presence of 
stereoisomerism in some substances was noted.  
Physio-Chem & 
Molecular Properties 
Empirical: 
low 
Modelled: 
low 
High All category members are appropriately similar with 
respect to key physicochemical and molecular 
properties. There is a high degree of consistency 
between measured and model estimated values. 
Substituents, 
Functional Groups, & 
Extended Structural 
Fragments 
Low-to-medium High Substituents and functional groups are consistent across 
all category members. There is a complex extended 
structural fragment (see Table 1) which is accounted for 
in sub-categorisation 
Transformation/Toxico
kinetics and Metabolic 
Similarity 
Empirical:  
   In vivo: none 
   In vitro: low 
 
Simulated: 
   low 
Medium Due to the small size range, bioavailability is not 
considered a factor in these predictions. Based on high 
quality data for two category members, there is 
evidence for similar toxicokinetics and metabolic 
pathways. There is metabolic evidence suggesting some 
methyl-substitution affects the rate of metabolites. In 
vivo data suggests the rate of metabolism affects chronic 
toxicity. This can be accounted for sub-categorisation. 
Potential Metabolic 
Products 
Simulated: 
  low 
High Based on in silico metabolic simulations, metabolites 
from oxidation are predicted to be produced by the 
category members. 
Toxicophores 
/Mechanistic alerts 
Medium High Based on in silico profilers, category members contain 
established toxicophores for protein and DNA binding 
via metabolic activation. However, the potency of 
protein binding varies between the five sub-structure 
groups. Potency differences can be accounted for sub-
categorisation. 
Similarity 
Parameter 
Data 
Uncertainty a 
Strength of 
Evidence b 
Comment 
Mechanistic 
plausibility and AOP-
Related Events 
Medium High The available AOP leads to the hypothesis that the 
mode of toxic action of all category members is related 
to oxidative metabolism to corresponding , -
unsaturated electrophilic aldehydes or , -unsaturated 
ketones. 
other relevant, in vivo, 
in vitro and ex vivo 
endpoints 
Low High Fish in vivo data and in vitro data for cellular effects are 
in agreement with the electrophilic reactivity hypothesis 
for rodent repeated-dose toxicity. 
a Uncertainty associated with underlying information/data used in the exercise (empirical, modelled; low, medium, 
high) 
b Consistency within the information/data used to support the similarity rational and prediction (low, medium, high)  
 
3.3.2 Uncertainty in toxicokinetic similarity 
The narrow range of carbon atoms of the applicability domain limits the impact of analogues on 
absorption and distribution (i.e., bioavailability). The most likely metabolic pathway of all 
analogues under consideration is considered to be metabolism via ADH oxidation to similar, but 
not identical, reactive derivatives, which elicit the same mechanism of chemical reactivity (i.e., 
Michael addition). This metabolic activation is supported indirectly by the results of the liver 
profusion studies by Strubelt et al. [18]. However, other metabolic mechanisms, such as ROS 
formation or P450 activation, while unlikely, are not completely ruled out by the information 
presented in this study. 
 
3.3.3 Uncertainty in toxicodynamic similarity 
Primary and secondary β-olefinic alcohols are experimentally associated with the pro-
electrophilic mode of toxic action. This mode of action is well-studied, and the molecular 
mechanism, soft electrophilic reactivity, is well understood. There is a qualitative Adverse 
Outcome Pathway (AOP) available linking electrophilic reactivity via ADH-mediated 
metabolism to cellular necrosis and/or apoptosis [45]. It is evident that oral repeated-dose 
toxicity of primary and secondary β-olefinic alcohols is related to this molecular mechanism. 
However, there is conflicting evidence as to whether the mode of action results in liver fibrosis. 
This conflicting evidence is the major source of uncertainty associated with toxicodynamic 
uncertainty. 
In an effort to further reduce uncertainties, the category was examined within and between 
structural sub-categories. Results for selected compounds representing each of the five sub-
structural groups from the ex vivo assay, the 2-hour rat isolated perfused liver, are consistent with 
the mechanistic hypothesis of metabolic activation via ADH to soft electrophiles. Specifically, 
all primary and secondary -olefinic alcohols tested exhibit a dramatic reduction (90-99%) in 
glutathione (GSH) as compared to controls. In chemico reactivity data, in the form of the 
concentration eliciting a 50% reduction in free GSH after 2 hours exposure for selected , -
unsaturated carbonyl compounds (i.e., potential reactive metabolites of -olefinic alcohols) also 
support the applicability domain of this chemical category. All , -unsaturated carbonyl 
compounds such as those derived from hepatic metabolism of primary and secondary -olefinic 
alcohol readily react with GSH. Specifically, , -unsaturated carbonyl derivatives of straight-
chain alcohols: allyl alcohol, 1-alken-3-ols and 2-alken-1-ols exhibit 2-hour RC50 values between 
0.05 and 0.40 mM, while those of branched alcohols: 2-methyl-2-alken-1-ols, 3-methyl-2-alken-
1-ols, 3-methyl-3-alken-2-ols and 4-methyl-3-alken-2-ols exhibit RC50 values between 12-22 
mM. 
The ex vivo and in chemico data (see Tables 2 and 3) support the premise that the single source 
substance, 2-propen-1-ol is potentially one of the most potent analogues and can be read across 
to other -alkenols, especially primary ones. 
Endpoint specific factors affecting the prediction include the uncertainty associated with how 
exactly the molecular structure impacts repeated-dose toxicity. These uncertainties are 
considered low to moderate since the most likely metabolites are well-studied Michael acceptors, 
either a -unsaturated aldehyde or a -unsaturated ketone. Since results from cytotoxicity, fish 
toxicity and skin sensitization studies reveal similar structure-activity relationships, no endpoint 
non-specific factors affecting the predictions are identified. 
The in chemico data, but not the ex vivo data, support the argument for sub-categorisation. In the 
sub-categorisation scheme 2-propen-1-ol can be read-across to the other straight-chained 
alcohols, such as 1-alken-3-ols and 2-alken-1-ols, with less uncertainty (i.e., greater confidence) 
than to the branched ones, 2-methyl-2-alken-1-ols, 3-methyl-2-alken-1-ols, 3-methyl-3-alken-2-
ols and 4-methyl-3-alken-2-ols. 
As reported in Table 3, high quality in chemico data exist for 14 of the 16 category members 
based on the proposed α, β-unsaturated metabolites and their reactivity with GSH. These 14 
derivatives include more than one representative of four of the five structural sub-groups (the 
other group has only a single analogue). All 14 analogues exhibit GSH reactivity and there is 
consistent potency within the two sub-categories: straight-chained and branched. Specifically, 
the results showed that -olefinic alcohols with a methyl group substituted on a vinyl C-atom are 
100 times less reactive than the non-methyl-substituted -olefinic alcohol. However, this 
difference in in chemico reactivity between substituted and unsubstituted -olefinic alcohols is 
not exhibited ex vivo in liver profusion tests. In order to reduce the toxicodynamic uncertainty to 
an acceptable level, without the need for further information or testing, it is recommended the 
read-across prediction only be applied to the straight-chain sub-category (i.e., alcohols 2-10 in 
Table 1). 
 3.3.4 Uncertainty in mechanistic relevance and completeness 
Assessment of uncertainty associated with mechanistic relevance and completeness of the read-
across is presented in Table 5. Uncertainty associated with mechanistic relevance and 
completeness of the read-across is judged to be medium. Briefly, uncertainty associated with this 
read-across stems from the facts that: 1) the single source substance, allyl alcohol, is a unique β-
olefinic alcohol and is metabolised to a unique electrophile, acrolein, 2) the most likely mode-of-
action, liver fibrosis is not consistently supported by the rat oral repeated-dose toxic data, and 3) 
ADH metabolic activation is central to the hypothesis; however other transformation 
mechanisms, such as autooxidation, ROS formation or P450 activation, cannot be overlooked. 
 
Table 5. Assessment of uncertainty associated with mechanistic relevance and completeness of the read-
across. 
Factor Uncertaintya Comment 
The problem and 
premise of the read-
across 
Low-to-medium; limited 
by lack of experimental 
support for mechanistic 
plausibility 
The endpoint to be read across, oral 90-day repeated-dose 
toxicity for primary and secondary β-olefinic alcohols is not 
well-studied. The scenario of the read-across hinges on 
metabolic similarity and the formation of electrophilic , -
unsaturated aldehydes and , -unsaturated ketones which 
elicit similar reactive potency leading to hepatic and renal 
effects related to apoptosis and necrosis. 
In vivo data read across 
Number of analogues 
in the source set 
Medium; 1 of 10 There is only one suitable category member (2-propen-1-ol) 
with in vivo apical endpoint data. This source substance 
represents the straight-chained sub-category  
Quality of the in vivo 
apical endpoint data 
read across 
Low  High quality empirical data for the stated regulatory endpoint 
exists from multiple studies for 2-propen-1-ol. These data are 
consistent in regards to qualitative and quantitative 
descriptions of effects. 
Severity of the apical 
in vivo hazard 
Low  Potency data for the in vivo apical endpoint are NOAELs for 
2-propen-1-ol include 6 mg/kg body weight bw/d in males 
based on increase in relative weight of liver, and 25 mg/kg 
bw/d in females based on bile duct hyperplasia and periportal 
hepatocyte hypertrophy in the liver. 
Evidence to the biological argument for RA 
Robustness of 
analogue data set 
Low-to-medium; ex vivo 
and in chemico 
endpoints reveal the 
same structure-activity 
relationships. 
The available data from ex vivo studies of category members 
are of high quality but limited to one representative 
compound of the five structural sub-groups. The available 
data from in chemico studies for the category members are 
robust, representing multiple chemicals in four of the five 
structural sub-groups. All the tests were judged to be reliable 
and conducted under the appropriate conditions. 
Concordance with 
regard to the 
intermediate and 
apical effects and 
potency data 
Medium While data are limited, there appears to be good agreement 
between the sequences of biochemical and physiological 
events leading to the in vivo toxicity. There is consistency 
and high specificity for the association between in vivo 
symptoms, and the ex vivo data as well as the structural 
domain of the category. There is general agreement among 
the dose-response relationships of the tested category 
members for the relevant in chemico event. Limiting the final 
domain to straight-chain derivatives markedly improves the 
concordance. 
Weight of Evidence Low-to-medium Overall the available information is consistent with the stated 
premise. The variation in structural (i.e., complex extended 
fragment) of the initial category weakens the WoE. While the 
toxicokinetics data are limited, the high quality ex vivo data 
(i.e., profused liver) support metabolism being a key factor to 
the category and add to the WoE. The fact that there is 
consistent relevant in chemico data for most if not all the 
category members strengthens the WoE. The lack of 
consistency between the in chemico data and the ex vivo data 
detracts from the WoE. Limiting the final domain to straight-
chain derivatives markedly improves the WoE. 
a Uncertainty: low, medium, high 
 
4 Discussion 
The overall chemical similarity of the-olefinic alcohols considered is limited by the complexity 
of the extended fragment but enhanced by clustering into sub-categories. Within the primary and 
secondary -olefinic alcohols data similarity and WoE associated with the fundamentals of 
toxicokinetic is the major weakness as there is uncertainty associated with the metabolite 
pathway and rate of metabolism. This uncertainty is reduced when the ex vivo liver perfusion 
data (see Table 2) are considered. Within the primary and secondary -olefinic alcohol category 
data similarity and WoE associated with toxicodynamics is a secondary weakness. This is, in 
large part, due to having a single source substance and the disparity in in vivo data for 2-propen-
1-ol and 3-methyl-2-buten-1-ol (see Table 8 of the supplemental information). While 2-propen-
1-ol was administered via gavage in a protocol similar to OECD TG408, in the 3-methyl-2-
buten-1-ol study, rats were exposed via drinking water and decreased water consumption was 
only noted. The administration via drinking water reduces the alcohol dosage, which in turn is 
likely to reduce toxicity. Uncertainties associated with mechanistic relevance and completeness 
of the read-across (i.e., uncertainty in the predictions) are reduced with the addition of in 
chemico data (see Table 3), as well as sub-categorisation. 
In order to reduce the uncertainties further, there is a need to secure further information by 
targeted testing. Of particular value would be data from in vitro assays quantifying hepatocyte 
metabolism and fibrosis-related activities. For example, an in vitro model consisting of hepatic 
organoids (3D co-culture) of human hepatocyte-like cells (HepaRG and primary human hepatic 
stellate cells (HSC)) can be used [51]. This system has been shown to maintain good hepatocyte 
functionalities and maintain HSCs in a quiescent-like state for 3 weeks. During this period, the 
3D HepaRG/HSC co-culture model has been validated for drug-induced toxicity and fibrosis 
assays using compounds such as methotrexate and allyl alcohol [51]. Another in vitro method, 
with potential application to this case study uses the HepG2 BAC-GFP reporter system [52]. 
Briefly, stress response activation of SRXN1, a target of the transcription factor NRF2, which is 
activated upon oxidative stress, and stress response activation of p21 and BTG2, both targets of 
the transcription factor p53, which is activated upon DNA damage, were evaluated [52]. Stress 
response activation is evaluated at various times after exposure using Nikon confocal 
microscopy. HepG2 cells can be cultured in conventional 2D monolayer and 3D hydrogel-based 
assays; green fluorescent protein (GFP) pixel intensity can be measured per single cell for 2D 
monolayer or measured per spheroid in 3D [53]. 
 
5 Conclusions 
While a submission for regulatory purposes may take on a different format, the present case 
study illustrates the key issues associated with modern day read-across and the use of non-animal 
data to support the prediction. In the end, the applicability domain for this case study is limited to 
small (C3 to C6), straight-chain, primary and secondary -olefinic alcohols. The oral 90-day 
repeated-dose NOAEL of 6 and 25 mg/kg bw/d, in male and female rats, respectively, reported 
for 2-propen-1-ol can be read across to untested straight-chained β-olefinic alcohols (i.e., 1-
alken-3-ols and 2-alken-1-ols) with acceptable uncertainty as a worst case scenario. Greater 
uncertainty is associated with read-across to the branched primary and secondary -olefinic 
alcohols.  
The mechanistic argument is consistent with primary and secondary -olefinic alcohols being 
readily metabolised by ADH to polarised α, -unsaturated aldehydes and ketones, which react 
via Michael addition interaction with thiols in proteins resulting in cellular apoptosis and/or 
necrosis. Upon oral repeated-dose exposure, the latter may, as in the case of 2-propen-1-ol, lead 
to in vivo toxicity involving the kidney and liver. The main route of exposure for -olefinic 
alcohols is oral with immediate absorption from the upper gastrointestinal tract. They are 
distributed unbound in the blood and are subsequently readily enzymatically oxidised, especially 
in the liver to reactive metabolites. 
The key element of uncertainty in accepting read-across predictions is rooted in metabolism. 
Specifically, the pivotal issues for establishing category membership include: 1) are the β- 
olefinic alcohols transformed to metabolites having the same mechanism of electrophilic 
reactivity, 2) is the metabolic pathway the same, 3) are the rates of transformation sufficient so 
the reactive metabolites are the definitive toxicant for the endpoint being read across, and 4) are 
the metabolites similar in reactive potency. 
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Supplementary material 
Read-Across of 90-Day Rat Oral Repeated-Dose Toxicity: A Case Study for Selected β-olefinic Alcohols 
 
Tables for Assessing Similarity of Analogues and Category Members for Read-Across 
Table 1. Comparison of Substance Identification, Structure and Chemical Classifications 
ID Name CAS No: SMILES 2D Structure 
Molecular 
Formula: 
1 2-propen-1-ol 107-18-6 C(CO)=C 
 
C3H6O 
2 2-buten-1-ol 6117-91-5 OCC=CC 
 
C4H8O 
3 2-penten-1-ol 20273-24-9 CCC=CCO 
 
C5H10O 
4 2-hexen-1-ol 2305-21-7 CCCC=CCO 
 
C6H12O 
ID Name CAS No: SMILES 2D Structure 
Molecular 
Formula: 
5 1-buten-3-ol 598-32-3 CC(C=C)O 
 
C4H8O 
6 1-penten-3-ol 616-25-1 CCC(C=C)O 
 
C5H10O 
7 1-hexen-3-ol 4798-44-1 CCCC(C=C)O 
 
C6H12O 
8 3-penten-2-ol 1569-50-2 CC=CC(C)O 
 
C5H10O 
9 3-hexen-2-ol 42185-97-7 CC(O)C=CCC 
 
C6H12O 
10 4-hexen-3-ol 4798-58-7 CCC(C=CC)O 
 
C6H12O 
ID Name CAS No: SMILES 2D Structure 
Molecular 
Formula: 
11 2-methyl-2-propen-1-ol 513-42-8 CC(=C)CO 
 
C4H8O 
12 2-methyl-2-buten-1-ol 4675-87-0 CC=C(C)CO 
 
C5H10O 
13 2-methyl-2-penten-1-ol 1610-29-3 CCC=C(C)CO 
 
C6H12O 
14 3-methyl-2-buten-1-ol 556-82-1 CC(=CCO)C 
 
C5H10O 
15 3-methyl-3-penten-2-ol 2747-53-7 CC(O)C(C)=CC 
  
C6H12O 
16 4-methyl-3-penten-2-ol 4325-82-0 CC(O)C=C(C)C 
 
C6H12O 
 
Table 2. Comparison of Physico-Chemical and Molecular Properties1 
ID Name 
Molecular 
Weight 
[g/mol] 
Log 
Kowa 
Vapor Pressureb 
[Pa at 25 deg C] 
Densityd 
[g/cm3] 
Melting 
Point b 
[deg C] 
Water 
Solubilityc 
Boiling 
Pointb 
[deg C] 
pKae 
1 2-propen-1-ol 58.08 
0.21 
0.17 (M) 
3.12x103 
3.48x103(M) 
0.8±0.1 
-76.37 
-129 (M) 
3.177 x105 
1 x106 (M) 
88.13 
97 (M) 
14.43 
2 2-buten-1-ol 72.11 0.63 794 0.8±0.1 
-62.76 
<-30 (M) 
1.272 x105 
1.66 x105 (M) 
121.10 
123 (M) 
14.7 
3 2-penten-1-ol 86.13 1.12 351 0.8±0.1 -50.48 4.572 x104 
143.87 
138 (M) 
14.7 
4 2-hexen-1-ol 100.16 1.61 121 0.8±0.1 -38.47 1.6 x104 
165.73 
157 (M) 
14.45 
5 1-buten-3-ol 72.11 0.63 3.29x103 0.8±0.1 -77.70 1.259 x10
4 89.94 
96-97 (M) 
14.49 
6 1-penten-3-ol 86.13 1.12 1.22x103 0.8±0.1 -65.08 
4.526 x104 
9.01 x104 (M) 
113.89 
115 (M) 
14.49 
7 1-hexen-3-ol 100.16 1.61 437 0.8±0.1 -52.76 
1.58 x104 
2.52 x104 (M) 
136.94 
134 (M) 
14.49 
8 3-penten-2-ol 86.13 1.04 802 0.8±0.1 -64.13 
5.283 x104 
8.92 x104 (M) 122.82 
14.77 
9 3-hexen-2-ol 100.16 1.53 231 0.8±0.1 -51.87 1.849 x10
4 145.52 14.77 
10 4-hexen-3-ol 100.16 1.53 231 0.8±0.1 -51.87 
1.849 x104 
3.81 x104 (M) 
145.52 
14.77 
11 
2-methyl-2-propen-
1-ol 
72.11 0.76 199 0.8±0.1 -72.59 
9.757 x104 
1.94 x105 (M) 105.69 
14.49 
12 
2-methyl-2-buten-
1-ol 
86.13 1.17 356 0.8±0.1 -59.25 4.094 x10
4 137.75 
14.87 
13 
2-methyl-2-penten-
1-ol 
100.16 1.66 66.7 0.8±0.1 -47.16 1.433 x10
4 159.86 
167.5 (M) 
14.86 
14 
3-methyl-2-buten-
1-ol 
98.1 1.17 314 0.8±0.1 -59.25 4.094 x10
4 137.75 
140 (M) 
14.83 
15 
3-methyl-3-penten-
2-ol 
100.16 1.59 325 0.8±0.1 -60.63 1.655 x10
4 139.41 
14.94 
16 
4-methyl-3-penten-
2-ol 
100.16 1.59 325 0.8±0.1 -60.63 1.655 x10
4 139.41 
14.9 
1Values typically derived from EPISuite v4.1; a KOWWIN Program (v1.68); b MPBPWIN v1.43; c at 25 deg C (mg/L) Kow (WSKOW v1.42);  
d ACD/Lab Percepta Platform - PhysChem Module (from ChemSpider); e ACD (Advanced Chemistry Development Inc., Toronto, Canada) 
(M): measured: Hansch, C et al. (1995); Yalkowsky, SH & Dannenfelser, RM (1992); Beilstein database.  
 
 
  
Table 3. Comparison of Substituents, Functional Groups, and Extended Structural Fragments 
 
ID Name Key 
Substituent(s) 
Functional Group(s) Chemical Class: Chemical Sub-
Class: 
1 2-propen-1-ol β-Olefin (C=C) External hydroxyl External C=C β-unsaturated alcohols primary allylic 
2 2-buten-1-ol β-Olefin (C=C) External hydroxyl Internal C=C β-unsaturated alcohols primary allylic 
3 2-penten-1-ol β-Olefin (C=C) External hydroxyl Internal C=C β-unsaturated alcohols primary allylic 
4 2-hexen-1-ol β-Olefin (C=C) External hydroxyl Internal C=C β-unsaturated alcohols primary allylic 
5 1-buten-3-ol β-Olefin (C=C) Internal hydroxyl External C=C β-unsaturated alcohols secondary allylic 
6 1-penten-3-ol β-Olefin (C=C) Internal hydroxyl External C=C β-unsaturated alcohols secondary allylic 
7 1-hexen-3-ol β-Olefin (C=C) Internal hydroxyl External C=C β-unsaturated alcohols secondary allylic 
8 3-penten-2-ol β-Olefin (C=C) Internal hydroxyl Internal C=C β-unsaturated alcohols secondary allylic 
9 3-hexen-2-ol β-Olefin (C=C) Internal hydroxyl Internal C=C β-unsaturated alcohols secondary allylic 
10 4-hexen-3-ol β-Olefin (C=C) Internal hydroxyl Internal C=C β-unsaturated alcohols secondary allylic 
11 2-methyl-2-propen-1-ol β-Olefin (C=C) 
Methyl 
External hydroxyl External C(C)=C β-unsaturated alcohols primary allylic 
12 2-methyl-2-buten-1-ol β-Olefin (C=C) 
Methyl 
External hydroxyl Internal C(C)=C β-unsaturated alcohols primary allylic 
13 2-methyl-2-penten-1-ol β-Olefin (C=C) 
Methyl 
External hydroxyl Internal C(C)=C β-unsaturated alcohols primary allylic 
14 3-methyl-2-buten-1-ol β-Olefin (C=C) 
Methyl 
External hydroxyl Internal C(C)=C β-unsaturated alcohols primary allylic 
15 3-methyl-3-penten-2-ol β-Olefin (C=C) 
Methyl 
Internal hydroxyl Internal C(C)=C β-unsaturated alcohols secondary allylic 
16 4-methyl-3-penten-2-ol β-Olefin (C=C) 
Methyl 
Internal hydroxyl Internal C(C)=C β-unsaturated alcohols secondary allylic 
  
 
Table 4. Comparison of Abiotic Transformation and Toxicokinetics 
 
ID Name Abiotic Transformation Toxicokinetics 
1 2-propen-1-ol Photodegradation: half-life = 4.32 hrs; rate 
constant = 2.59x10-11 cm3/molecule-seca 
Rapidly metabolised to acrolein by alcohol 
dehydrogenase; can be further oxidised to 
carboxylic acids and finally to CO2; Tmax = 30-60 
mina 
Km= 0.05 mM (binding affinities for human alcohol 
dehydrogenase), V= 10.3 (turnover no. X active 
site-1 X min-1)b 
2 2-buten-1-ol  Km= 0.01 mM (binding affinities for human alcohol 
dehydrogenase), V= 13.0 (turnover no. X active 
site-1 X min-1)b 
3 2-penten-1-ol   
4 2-hexen-1-ol  Km= 0.003 mM (binding affinities for human 
alcohol dehydrogenase), V= 15.5 (turnover no. X 
active site-1 X min-1)b 
5 1-buten-3-ol   
6 1-penten-3-ol   
7 1-hexen-3-ol   
8 3-penten-2-ol   
9 3-hexen-2-ol   
10 4-hexen-3-ol   
11 2-methyl-2-propen-1-
ol 
  
12 2-methyl-2-buten-1-ol   
13 2-methyl-2-penten-1-
ol 
  
14 3-methyl-2-buten-1-ol  Km= 0.0045 mM (binding affinities for human 
alcohol dehydrogenase), V= 13.0 (turnover no. X 
active site-1 X min-1)b 
15 3-methyl-3-penten-2-
ol 
  
16 4-methyl-3-penten-2-
ol 
  
a OECD SIDS Allyl Alcohol; b Pietruszko, R., Crawford, K. & Lester, D. 1973. Arch. Biochem. Biophys., 159, 50-60 
Table 5. Comparison of Potential Metabolic Products 
ID Name 
Liver metabolism simulator 
Toolbox v3.3.5 MetaPrint2D-React 
software 
Meteor Nexus 
Rat liver S9 Skin metabolism 
1 2-propen-1-ol Oxidation (1) Oxidation (1) 
Epoxidation 
Oxidation 
Epoxidation (1) 
Oxidation (1) 
2 2-buten-1-ol 
Hydroxylation (1) 
Oxidation (1) 
Oxidation (1) 
Hydroxylation 
Oxidation 
Acylation 
Hydroxylation (1) 
Oxidation (1) 
Epoxidation (1) 
3 2-penten-1-ol 
Hydroxylation (1) 
Oxidation (1) 
Hydroxylation (1) 
Oxidation (1) 
Oxidation 
Acylation 
Hydroxylation (2) 
Oxidation (1) 
Epoxidation (1) 
4 2-hexen-1-ol 
Hydroxylation (2) 
Oxidation (1) 
Hydroxylation (2) 
Oxidation (1) 
Hydroxylation 
Oxidation 
Acylation 
Hydroxylation (3) 
Oxidation (1) 
Epoxidation (1) 
5 1-buten-3-ol Oxidation (1) Hydroxylation (1) 
Epoxidation 
Epoxidation/Hydrolysi
s 
Oxidation (1) 
Hydroxylation (1) 
Epoxidation (1) 
6 1-penten-3-ol 
Hydroxylation (1) 
Oxidation (1) 
Hydroxylation (2) Hydroxylation 
Hydroxylation (2) 
Oxidation (1) 
Epoxidation (1) 
7 1-hexen-3-ol 
Hydroxylation (2) 
Oxidation (1) 
Hydroxylation (2) 
Hydroxylation 
Oxidation 
Acetylation 
Oxidation (1) 
Hydroxylation (3) 
Epoxidation (1) 
8 3-penten-2-ol Oxidation (1) Hydroxylation (1) 
Hydroxylation 
Oxidation 
Epoxidation 
Oxidation (1) 
Hydroxylation (2) 
Epoxidation (1) 
9 3-hexen-2-ol 
Hydroxylation (1) 
Oxidation (1) 
Hydroxylation (2) 
Hydroxylation 
Oxidation 
Alkylation 
Oxidation (1) 
Hydroxylation (3) 
Epoxidation (1) 
10 4-hexen-3-ol 
Hydroxylation (2) 
Oxidation (1) 
Hydroxylation (2) 
Hydroxylation 
Oxidation 
Acetylation 
Oxidation (1) 
Hydroxylation (3) 
Epoxidation (1) 
11 2-methyl-2-propen-1-ol Oxidation (1) No metabolism No metabolism 
Oxidation (1) 
Hydroxylation (1) 
12 2-methyl-2-buten-1-ol Oxidation (1) Hydroxylation (1) 
Acetylation 
Acylation 
Hydroxylation (2) 
Oxidation (1) 
Epoxidation (1) 
13 2-methyl-2-penten-1-ol 
Hydroxylation (1) 
Oxidation (1) 
Hydroxylation (1) 
Hydroxylation 
Oxidation 
Acetylation 
Acylation 
Dehydroxylation 
Hydroxylation (3) 
Oxidation (1) 
Epoxidation (1) 
14 3-methyl-2-buten-1-ol 
Hydroxylation (1) 
Oxidation (1) 
No metabolism 
Hydroxylation 
Oxidation 
Alkylation  
Acylation 
Hydroxylation (2) 
Oxidation (1) 
Epoxidation (1) 
15 3-methyl-3-penten-2-ol Oxidation (1) Hydroxylation (2) 
Hydroxylation 
Oxidation 
Acetylation 
Oxidation (1) 
Hydroxylation (3) 
Epoxidation (1) 
16 4-methyl-3-penten-2-ol Oxidation (1) Hydroxylation (1) 
Hydroxylation 
Oxidation 
Alkylation 
Oxidation (1) 
Hydroxylation (3) 
Epoxidation (1) 
 () - The number of metabolites for specific transformation. 
Table 6A. Comparison of Toxicophores for β-unsaturated alcohols 
 
ID Name Toxicophores1 
Structural alerts1,2 
DNA binding 
by OECD1 
Protein 
binding by 
OECD1 
Protein 
binding 
potency 
(GSH)1 
In vivo 
mutagenicity 
(Micronucleus
) alerts by ISS1 
Mitochondria 
toxicity2 
1 2-propen-1-ol Cramer Class III No alert No alert Not classified No alert Alert  C=CCO 
2 2-buten-1-ol Cramer Class I No alert No alert Not classified No alert Alert  C=CCO 
3 2-penten-1-ol Cramer Class I No alert No alert Not classified No alert Alert  C=CCO 
4 2-hexen-1-ol Cramer Class I No alert No alert Not classified No alert Alert  C=CCO 
5 1-buten-3-ol Cramer Class III No alert No alert Not classified No alert Alert  C=CCO 
6 1-penten-3-ol Cramer Class III No alert No alert Not classified No alert Alert  C=CCO 
7 1-hexen-3-ol Cramer Class III No alert No alert Not classified No alert Alert  C=CCO 
8 3-penten-2-ol Cramer Class II No alert No alert Not classified No alert Alert  C=CCO 
9 3-hexen-2-ol Cramer Class II No alert No alert Not classified No alert Alert  C=CCO 
10 4-hexen-3-ol Cramer Class II No alert No alert Not classified No alert Alert  C=CCO 
11 
2-methyl-2-
propen-1-ol 
Cramer Class III No alert No alert Not classified No alert Alert  C=CCO 
12 
2-methyl-2-buten-
1-ol 
Cramer Class I No alert No alert Not classified No alert Alert  C=CCO 
ID Name Toxicophores1 
Structural alerts1,2 
DNA binding 
by OECD1 
Protein 
binding by 
OECD1 
Protein 
binding 
potency 
(GSH)1 
In vivo 
mutagenicity 
(Micronucleus
) alerts by ISS1 
Mitochondria 
toxicity2 
13 
2-methyl-2-
penten-1-ol 
Cramer Class I No alert No alert Not classified No alert Alert C=CCO 
14 
3-methyl-2-buten-
1-ol 
Cramer Class I No alert No alert Not classified No alert Alert C=CCO 
15 
3-methyl-3-
penten-2-ol 
Cramer Class I No alert No alert Not classified No alert Alert C=CCO 
16 
4-methyl-3-
penten-2-ol 
Cramer Class I No alert No alert Not classified No alert Alert  C=CCO 
1 OECD QSAR Toolbox 3.3.5; 2 COSMOS profiler available at: http://knimewebportal.cosmostox.eu/ 
Table 6B. Comparison of Toxicophores for metabolites 
ID Name Toxicophores1 
Structural alerts1 
DNA binding 
by OECD 
Protein 
binding by 
OECD 
Protein 
binding 
potency 
(GSH) 
Carcinogenicit
y (genotox and 
nongenotox) 
alerts by ISS 
In vivo 
mutagenicity 
(Micronucleus
) alerts by ISS 
1 
2-propenal 
(acrolein) Cramer Class II 
Michael 
addition 
Michael 
addition, Schiff 
Base Formers 
Extremely 
reactive  
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
2 
2-butenal 
(crotonal 
dehyde) 
Cramer Class I 
Michael 
addition 
Michael 
addition, Schiff 
Base Formers 
Highly 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
3 
trans-2-
pentenal 
Cramer Class I 
Michael 
addition 
Michael 
addition, Schiff 
Base Formers 
Highly 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
4 
trans-2-
hexenal 
Cramer Class I 
Michael 
addition 
Michael 
addition, Schiff 
Base Formers 
Highly 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
5 
methyl vinyl 
ketone 
Cramer Class II 
Michael 
addition 
Michael 
addition 
Extremely 
reactive  
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
ID Name Toxicophores1 
Structural alerts1 
DNA binding 
by OECD 
Protein 
binding by 
OECD 
Protein 
binding 
potency 
(GSH) 
Carcinogenicit
y (genotox and 
nongenotox) 
alerts by ISS 
In vivo 
mutagenicity 
(Micronucleus
) alerts by ISS 
6 
ethyl vinyl 
ketone 
Cramer Class II 
Michael 
addition 
Michael 
addition 
Extremely 
reactive  
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
7 
propyl vinyl 
ketone 
Cramer Class II 
Michael 
addition 
Michael 
addition 
Extremely 
reactive  
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
8 
3-penten-2-
one 
Cramer Class I 
Michael 
addition 
Michael 
addition 
Highly 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
9 3-hexen-2-one Cramer Class I 
Michael 
addition 
Michael 
addition 
Highly 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
10 4-hexen-4-one Cramer Class I 
Michael 
addition 
Michael 
addition 
Highly 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
ID Name Toxicophores1 
Structural alerts1 
DNA binding 
by OECD 
Protein 
binding by 
OECD 
Protein 
binding 
potency 
(GSH) 
Carcinogenicit
y (genotox and 
nongenotox) 
alerts by ISS 
In vivo 
mutagenicity 
(Micronucleus
) alerts by ISS 
11 
2-methyl 
acrolein 
Cramer Class II 
Michael 
addition 
Michael 
addition, Schiff 
Base Formers 
Moderately 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
12 
2-methyl-2-
butenal 
Cramer Class I 
Michael 
addition 
Michael 
addition, Schiff 
Base Formers 
Moderately 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
13 
2-methyl-2-
pentenal 
Cramer Class I 
Michael 
addition 
Michael 
addition, Schiff 
Base Formers 
Moderately 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
14 
3-methyl-2-
butenal 
Cramer Class I No alert  
Schiff Base 
Formers 
No MA alert 
Moderately 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
15 
3-methyl-3-
penten-2-one 
Cramer Class I 
Michael 
addition 
Michael 
addition 
Highly 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
ID Name Toxicophores1 
Structural alerts1 
DNA binding 
by OECD 
Protein 
binding by 
OECD 
Protein 
binding 
potency 
(GSH) 
Carcinogenicit
y (genotox and 
nongenotox) 
alerts by ISS 
In vivo 
mutagenicity 
(Micronucleus
) alerts by ISS 
16 
4-methyl-3-
penten-2-one 
Cramer Class I No alert  No alert  
Highly 
reactive 
Genotoxic 
carcinogenicity, 
α,β-unsaturated 
carbonyls 
α,β-
unsaturated 
carbonyls 
1 OECD QSAR Toolbox 3.3.5  
 
 
Table 7. Comparison of Mechanistic Plausibility and AOP-Related Event Data 
ID Name 
Mechanistic 
Plausibility 
Adverse 
Outcome 
Pathway or 
Mode of Toxic 
Action: 
Molecular 
Initiating Event: 
Key Event 
1 etc.: 
Key Event 
Relationshi
p 1 etc.: 
Other 
Mechanistical
ly-Relevant 
Events 
1 2-propen-1-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
2 2-buten-1-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
3 2-penten-1-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
4 2-hexen-1-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
5 1-buten-3-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
6 1-penten-3-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
7 1-hexen-3-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
8 3-penten-2-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
9 3-hexen-2-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
ID Name 
Mechanistic 
Plausibility 
Adverse 
Outcome 
Pathway or 
Mode of Toxic 
Action: 
Molecular 
Initiating Event: 
Key Event 
1 etc.: 
Key Event 
Relationshi
p 1 etc.: 
Other 
Mechanistical
ly-Relevant 
Events 
10 4-hexen-3-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
11 2-methyl-2-propen-1-
ol 
 Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
12 2-methyl-2-buten-1-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
13 2-methyl-2-penten-1-
ol 
 Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
14 3-methyl-2-buten-1-ol  Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
15 3-methyl-3-penten-2-
ol 
 Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
16 4-methyl-3-penten-2-
ol 
 Apoptosis or 
necrosis  
Covalent binding of 
reactive metabolite 
with thiols  
  Hepatotoxicity 
 
 
 
 
Table 8. Comparison of Toxicologically Relevant In Vivo, In Vitro and Ex Vivo Data 
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NOAEL (Repeat 
dose toxicity) 
3-11.6 (mg/kg 
bw/day) 
 
    
 
   
 
 
 
 65.4-82.1 
(mg/kg bw/day) 
  
20-400 (ppm)              [9]   
12 (mg/m3)                 
[1-5]                 
NOEL (Repeat 
dose toxicity) 
1.37 (mg/kg/day)                   
  
  
  
 14.4-21 (mg/kg 
bw/day) 
    
[6]                          [9]     
LOAEL (Repeat 
dose toxicity) 
47 (mg/m3)                   
  
  
  
243.8-307.2 
(mg/kg bw/day) 
    
6-34 (mg/kg/day)                          [9]     
[1, 4, 7]                               
LOEL (Repeat dose 
toxicity) 
4.8-87.1 
(mg/kg/day) 
                  
  
  
    
    
[2, 6, 8]                               
NOAEL 
(Reproductive 
toxicity) 
8 (mg/kg/day)                               
48.2-58.4 
(mg/m3) 
                  
  
  
    
    
[2, 3]                               
NOAEL 
(Teratogenicity) 
10 (mg/kg/day)                               
[10]                               
10 (mg/kg/day)                               
Endpoint 
Name 
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LOAEL (Maternal 
toxicity) [7]   
  
    
  
  
      
  
  
    
    
NOEL 
(Reproductive 
toxicity) 
40 (mg/kg/day)                               
[3]   
  
    
  
  
      
  
  
    
    
Carcinogenic/ 
Genotoxicity  
5 x Negative                               
[11-13]                               
LC50 
(Acute toxicity) 
140-2130 
(mg/m3)   
  
    
  
  
      
  
  
    
    
500 (mg/m3/2H                               
75 (ppm/8H)                               
50->400 (ppm)                               
[1, 5, 14-16]                               
LD50   
(Acute toxicity) 
37 -105 (mg/kg) 
1084 
-793 
(mg/
kg) 
  
3500 
(mg/
kg) 
50 70 450 
      
2924  
(pp
m) 
  
3  
(mL/
kg) 
810-3900     
[1,14, 16-20]    
    
(pp
m) 
(mg/
kg) 
(mg/
kg) 
      
2-
500  
(mg/
kg) 
  
4920 
(mg/
kg) 
(mg/kg)     
    
 
[21, 
37] 
  
[22] [17] [23] [24] 
      
[25] 
  
[26] [27-30] 
    
64-76 (U/L)                               
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Name 
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hepatic fibrosis [31]                               
Genotoxicity 
(AMES, 
Chromosomal 
aberration, gene 
mutation) 
6x Negative  5 x 
Positive      
  
    
  
  
      
  
  
   Negative  
    
[11, 13, 32-36] 
  
  
    
  
  
      
  
  
  [30] 
    
 
  
Endpoint 
Name 
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